RNA VACCINES PART 1: EXPLORING FUTURE POTENTIAL

Pushing the frontiers of mRNA formulation & delivery

Vaccine Insights 2023; 2(3), 106–110

DOI: 10.18609/vac.2023.020

Published: 23 April

Interview

Mohamed EH ElSayed

Charlotte Barker, Editor, Vaccine Insights, speaks to (pictured)
Mohamed EH ElSayed, EVP & Chief Technology Officer, RVAC Medicines, Inc

Please enter your email to access content

Welcome back to Bioinsights, please log in to access this content

Email address

Password

Forgotten password?

Please note all fields marked with an * are mandatory

Title*

First name*

Last name*

Email*

Password*

Country*

Job Title*

I would like to receive a weekly email newsletter and updates from BioInsights, subject to their Privacy Policy

To personalise your emails with updates relevant to you, please use the tick boxes below to select areas of interest:

Immuno-oncology
Cell & Gene Therapy
Vaccines
Nucleic Acid

Business Development/Licensing/Finance
Regulatory
Patents & IP
Clinical Trials
Supply Chain
Vectors
Cord Blood
Manufacturing
Preclinical R&D
Analytical/QA/QC/CMC
Discovery
Market Access/Pricing
Drug Delivery
Public Health
Bioanalytics

If you have any problem accessing our content, please email info@insights.bio

Terms & Conditions
Privacy Policy

RNA VACCINES PART 1: EXPLORING FUTURE POTENTIAL

Pushing the frontiers of mRNA formulation & delivery

Vaccine Insights 2023; 2(3), 106–110

DOI: 10.18609/vac.2023.020

Charlotte Barker, Editor, Vaccine Insights, speaks to (pictured)Mohamed EH ElSayed, EVP & Chief Technology Officer, RVAC Medicines, Inc

Charlotte Barker, Editor, Vaccine Insights, speaks to (pictured)
Mohamed EH ElSayed, EVP & Chief Technology Officer, RVAC Medicines, Inc